You searched for "bowel"

593 results found

Oestrogens and OAB

This is a multicentre study from Europe. The female genitals and lower urinary tract have a common embryological origin arising from urogenital sinus. Therefore, both could be sensitive to female sex steroid hormones. Oestrogens and progesterone receptors have been demonstrated...

Urinary tract infections and antibiotics – the debate goes on

A large number of hospital patients and primary care patients suffer from recurrent urinary tract infection (UTI) and urosepsis. Some of these patients end up in intensive care units with multi-organ failure. New draft guidance from the National Institute for...

Psychosocial distress in parents of children with DSD

Disorders of sex development (DSD) are a rare set of medical conditions with prevalence rates ranging between 1:00 to 1:5000 births. Secondary atypical genitalia is seen in a subset. Psychosocial aspects have until recently been understudied. We know that some...

Bladder cancer diagnosis and follow up: A new proven urinary biomarker to support the post COVID-19 recovery phase

Since lockdown began most urologists have been following the advice of BAUS Oncology, to minimise the risk of exposure of patients and staff to potential COVID-19 infection: the result is an increasing backlog of patients requiring tests to determine if...

Patients’ preferences for additional (cytoreductive) treatments to the prostate and metastasis in metastatic prostate cancer

Patients diagnosed with metastatic prostate cancer at first diagnosis or de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) have had reported increases in overall survival due to rapid advances and intensification of systemic therapy regimes beyond traditional androgen deprivation therapy...

Treatment options for renal cell carcinoma

In this issue of European Urology, experts review advancements and challenges in treating renal cell carcinoma (RCC), emphasising the complexity of managing a disease with an expanding array of therapeutic options. Despite significant progress, critical questions remain about treatment sequencing,...

The Prostate Cancer Foundation awards more than $6 million to promising young investigators to advance prostate cancer research

The Prostate Cancer Foundation (PCF) announced that its 2024 Young Investigator Award programme has awarded a total of $6.3 million in funding to 30 promising next-generation researchers conducting innovative prostate cancer research. The PCF programme, now in its 27th year,...

Mount Sinai Urology Chair Receives Honorary Fellowship From Prestigious Royal College

Ash K. Tewari, MBBS, MCh, FRCS (Hon.), DSc (Hon.), Chair of the Department of Urology at the Icahn School of Medicine at Mount Sinai in New York City and Director of the Center of Excellence for Prostate Cancer at the...

The future of bladder preservation for muscle-invasive bladder cancer

Localised muscle-invasive bladder cancer (MIBC) has historically been treated with radical cystectomy (RC), but bladder preservation therapy (BPT) has emerged as a credible and increasingly refined alternative. Early work by Herr in the 1980s demonstrated that radical transurethral resection of...

Nocturia – the Cinderella of lower urinary tract symptoms

Nocturia is defined as waking during the night (at least once) to urinate. The important part of the definition relates to the necessity of sleep to precede the episode (although whether sleep must follow the episode is less clear). The...

Erectile dysfunction part II: treatment

Introduction The identification of specific risk factors associated with erectile dysfunction (ED) allows patients with mild or moderate ED to undergo a series of lifestyle changes, which may provide enough improvement in the erectile function to avoid pharmacotherapies. Cessation of...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...